Experimental drug ampligen takes on chronic fatigue
NCT ID NCT00215813
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests an experimental drug called Ampligen (rintatolimod) in people with severe chronic fatigue syndrome (CFS). Participants receive twice-weekly IV infusions over several months. The goal is to see if the drug can ease symptoms and improve quality of life for those who have been sick for at least a year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ampligen (rintatolimod)
What this could lead to
If it works, this could point toward a treatment option for severe chronic fatigue syndrome, potentially reducing symptoms and improving daily function.
What could go wrong
This is an early open-label study with no placebo group, so results may be biased. The drug is not yet approved for CFS, and side effects or lack of benefit are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC FATIGUE SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hunter-Hopkins Center, PA
Charlotte, North Carolina, 28210, United States
-
Sierra Internal Medicine
Incline Village, Nevada, 89451, United States